HTB | HIV i-Base

News from EACS 2021, injectable ART in the UK, HIV cure research and more...

Featured HTB: no. 10 – plus HIV and COVID-19 (31 October 2021) 31 October 2021. Related: Editorial.
Featured CROI 2021: First results using capsid inhibitor lenacapavir against MDR HIV: potential for six-monthly ART and PrEP 1 April 2021. Related: Conference reports, Antiretrovirals, CROI 2021 (virtual).
Featured In memory: Timothy Ray Brown – the Berlin patient, the first person to be cured of HIV 14 October 2020. Related: In memory.
Selected islatravir studies stop enrolment: Further complications with important investigational drugs 6 December 2021. Related: Early access, Antiretrovirals.
IAS strategy for an HIV cure (2021): easy-to-read Q&A 1 December 2021. Related: Cure research.
HTB: no. 11 – plus HIV and COVID-19 (Nov/Dec 2021) 30 November 2021. Related: Editorial.
IAS review on HIV cure research: A global scientific strategy to cure HIV (2021) 30 November 2021. Related: Editorial.
i-Base appeal: please support i-Base with £5 or £10 a month 30 November 2021. Related: Editorial.
18th International European AIDS Conference (EACS 2021) 30 November 2021. Related: Conference reports, EACS 18 London 2021.
Lenacapavir: drug resistance after viral rebound in treatment experienced participants 30 November 2021. Related: Conference reports, Antiretrovirals, Resistance, EACS 18 London 2021.
Implications of historical M184V on use of dual dolutegravir/lamivudine ART 30 November 2021. Related: Conference reports, Antiretrovirals, Resistance, EACS 18 London 2021.
Stopping long-acting cabotegravir/rilpivirine: 1 in 5 trial participants didn’t restart oral ART within eight weeks 30 November 2021. Related: Conference reports, Antiretrovirals, EACS 18 London 2021.
Islatravir plus doravirine dual ART: 144 week follow-up from phase 2 study 30 November 2021. Related: Conference reports, Antiretrovirals, EACS 18 London 2021.
HIV-specific mental health services across the EU 30 November 2021. Related: Conference reports, Coinfections and complications, EACS 18 London 2021.
NICE approves long-acting cabotegravir and rilpivirine injections in England and Wales 30 November 2021. Related: Antiretrovirals, Treatment access.
MSD/Merck stop once-weekly NNRTI MK-8507: islatravir studies continue with closer monitoring 30 November 2021. Related: Antiretrovirals.
UK oral history project for young people who were born with HIV 30 November 2021. Related: Other news.
Colchicine: no clinical benefits against COVID-19 in pooled analysis of RCTs 30 November 2021. Related: COVID-19: investigational drugs, COVID-19.
Eli Lilly withdraw EU application for bNAbs etesevimab and bamlanivimab 30 November 2021. Related: COVID-19: investigational drugs, COVID-19.
Future meetings and webinars 2021/2022 30 November 2021. Related: Future meetings.
HTB: no. 11 – plus HIV and COVID-19 (30 November 2021) 30 November 2021. Related: PDFs.
18th International European AIDS Conference (EACS 2021) 31 October 2021. Related: Conference reports, Conference index, EACS 18 London 2021.
EACS 2021: a call for collaborations and for both HIV and COVID-19 31 October 2021. Related: Conference reports, Treatment strategies, HIV prevention and transmission, EACS 18 London 2021.
Reduced responses to COVID-19 vaccines at low CD4 counts 31 October 2021. Related: Conference reports, COVID-19: HIV and COVID-19 coinfection, COVID-19, EACS 18 London 2021.
EACS Guidelines: 11th edition (October 2021) 31 October 2021. Related: Conference reports, Guidelines, EACS 18 London 2021.
Community “Respect my HIV” march: 30 October 2021 in London 31 October 2021. Related: Conference reports, Treatment advocacy, EACS 18 London 2021.
NHS Scotland approves long-acting cabotegravir and rilpivirine injections 31 October 2021. Related: Antiretrovirals.
Early treatment prevents anal cancer in people living with HIV: ANCHOR study stops early 31 October 2021. Related: Cancer and HIV.
Benefits reported for continued use of cotrimoxazole prophylaxis at high CD4 counts in Malawi 31 October 2021. Related: Coinfections and complications.
Gilead withdraws application for F/TAF as PrEP in the EU 31 October 2021. Related: HIV prevention and transmission.
BHIVA guidelines for the management of HIV-2 (2021) 31 October 2021. Related: Guidelines, Coinfections and complications.
Explaining rare cases of HIV remission – and risk of viral rebound after many years off-ART 31 October 2021. Related: Cure research.
Switch study for people with insomnia using dolutegravir 31 October 2021. Related: Research studies.
CHAI 2021 HIV market report: the state of the HIV market in low- and middle-income countries 31 October 2021. Related: On the web.
Continued evidence for poorer COVID-19 outcomes in people with HIV 31 October 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19.
Immune responses to natural COVID-19 infection in HIV positive people 31 October 2021. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19.
Durability of immune responses to COVID-19 vaccines in HIV positive people 31 October 2021. Related: COVID-19: vaccine research, COVID-19.
Sputnik V vaccine not approved in South Africa due to potential increased risk of HIV 31 October 2021. Related: COVID-19: vaccine research, COVID-19.
Sanofi reports phase 1/2 mRNA results but withdraws from further COVID19 vaccines 31 October 2021. Related: COVID-19: vaccine research, COVID-19.
Early efficacy results with oral molnupiravir focuses attention on price and access 31 October 2021. Related: COVID-19: treatment access, COVID-19: investigational drugs, COVID-19.
HTB: no. 10 – plus HIV and COVID-19 (31 October 2021) 31 October 2021. Related: PDFs.
HTB: no. 9 – plus HIV and COVID-19 (17 September 2021) 17 September 2021. Related: Editorial.
11th IAS Conference on HIV Science (IAS 2021) 17 September 2021. Related: Conference reports, Conference index, IAS 11 virtual 2021.
IAS 2021 website now open access 17 September 2021. Related: Conference reports, On the web, IAS 11 virtual 2021.
Substudies from the ODYSSEY trial: results July 2021 17 September 2021. Related: Conference reports, Paediatric care, Paediatric Workshop 13 virtual 2021.
Trial design for next generation PrEP 17 September 2021. Related: Conference reports, IAS 11 virtual 2021.
Lenacapavir submitted to EMA for MDR HIV 17 September 2021. Related: Antiretrovirals.
Pipeline report 2021: HIV drugs in development 17 September 2021. Related: Special reports, Supplements, Pipeline report, Antiretrovirals.
Darunavir/ritonavir price now US $210 for global access 17 September 2021. Related: Treatment access.
HPV vaccine prevent penile infections in young gay men 17 September 2021. Related: Coinfections and complications.
Imbokodo trial results highlight challenge of developing an HIV vaccine and urgent need for access to proven prevention tools 17 September 2021. Related: HIV prevention and transmission, Vaccines and microbicides.
Moderna registers HIV vaccine study 17 September 2021. Related: HIV prevention and transmission, Vaccines and microbicides.